Efficacy and Safety of 400 μg Twice Daily of Aclidinium Bromide vs. Placebo When Administered to Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT01636401 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

INDUSTRY

Sponsor class

Conditions

COPD

Interventions

DRUG: aclidinium bromide 400 μg
DRUG: aclidinium bromide placebo

Sponsor

Daewoong Pharmaceutical Co. LTD.